Ciclesonide
A corticosteroid prodrug that is activated by airway esterases to its active metabolite des-ciclesonide, used as an inhaled therapy for persistent asthma and allergic rhinitis. Its prodrug design limits systemic absorption and local oropharyngeal side effects compared to some other inhaled corticosteroids. It provides effective anti-inflammatory control of airway disease with once-daily dosing.
分子量
540.7000 g/mol
LogP
5.30
TPSA
99.10 Ų
リピンスキーの五則
不適合
治療領域
作用機序
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
2D構造
Cite this structure
Embed this structure
SMILES
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
InChI
InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
Molecular Formula
C32H44O7
HBD / HBA
1 / 7
回転可能結合数
6
重原子数
39
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A corticosteroid prodrug that is activated by airway esterases to its active metabolite des-ciclesonide, used as an inhaled therapy for persistent asthma and allergic rhinitis. Its prodrug design limits systemic absorption and local oropharyngeal side effects compared to some other inhaled corticosteroids. It provides effective anti-inflammatory control of airway disease with once-daily dosing.
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Yes, Ciclesonide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2040682. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6918155. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ciclesonide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ciclesonide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ciclesonide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ciclesonide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ciclesonide"></drugfyi-drug>